Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
Status:
Recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of chidamide combined with
etoposide and cisplatin/carboplatin in the first-line treatment of advanced extrapulmonary
neuroendocrine carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Harbin Medical University The First Affiliated Hospital of Xiamen University